.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE10_Darunavir.Darunavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE10_Darunavir.Darunavir| name: | Darunavir |
| ATC code: | J05AE10 | route: | oral |
| n-compartments | 2 |
Darunavir is a protease inhibitor used as part of combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV-1) infection. It is approved for use in adults and children over 3 years old, often co-administered with ritonavir or cobicistat to enhance its pharmacokinetic properties.
Pharmacokinetic parameters reported for healthy HIV-infected adults after oral administration of darunavir (boosted with ritonavir 100 mg) 800 mg once daily.
Cojutti, PG, et al., & Pea, F (2020). Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clinical pharmacokinetics 59(10) 1251–1260. DOI:10.1007/s40262-020-00933-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32856282
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703
Dickinson, L, et al., & Siccardi, M (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. The Journal of antimicrobial chemotherapy 71(4) 1041–1045. DOI:10.1093/jac/dkv439 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26712906